Djursholm, Sweden

Lars Hammarström

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Biora Bioex Ab. Active years: 2007.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2007

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Lars Hammarström: Innovator in Pharmaceutical Composition

Introduction

Lars Hammarström is a notable inventor based in Djursholm, Sweden. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of inflammation. His innovative work has led to the development of a unique patent that addresses critical health issues.

Latest Patents

Lars holds a patent for a "Matrix protein composition for treating inflammation." This invention involves the use of active enamel substances for the preparation of pharmaceutical or cosmetic compositions aimed at healing wounds, improving soft tissue regeneration, and preventing or treating infections or inflammation. His patent is a testament to his commitment to advancing medical science and improving patient care.

Career Highlights

Lars Hammarström is associated with Biora Bioex AB, a company that focuses on innovative solutions in the healthcare sector. His work at Biora Bioex AB has allowed him to explore and develop groundbreaking technologies that have the potential to transform treatment methodologies.

Collaborations

Lars has collaborated with esteemed colleagues such as Stina Gestrelius and Petter Lyngstadaas. These partnerships have fostered an environment of innovation and creativity, leading to advancements in their respective fields.

Conclusion

Lars Hammarström's contributions to the pharmaceutical industry through his patent and collaborative efforts highlight his role as a key innovator. His work not only addresses pressing health concerns but also paves the way for future advancements in medical treatments.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…